NCT03121326

Brief Summary

With the rapid growth of the global elderly population, the studies of the biomarkers of the sarcopenia and aging are under investigation in different ways. The investigators use Metabolomics to explore the biomarkers of the sarcopenia and aging of the senior adults.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
650

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 6, 2017

Completed
9 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 15, 2017

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 17, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 20, 2017

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2017

Completed
Last Updated

May 19, 2017

Status Verified

March 1, 2017

Enrollment Period

9 days

First QC Date

April 17, 2017

Last Update Submit

May 17, 2017

Conditions

SarcopeniaAging

Keywords

SarcopeniaAgingBiomarkersMetabolomics

Outcome Measures

Primary Outcomes (1)

  • The biomarkers of the sarcopenia and aging in senior adults.

    Metabolomics to explore the biomarkers of the sarcopenia and aging.

    one year

Interventions

blood and urine samplingDIAGNOSTIC_TEST

Ten mL blood and 15mL urine are collected.

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

650 residents of the Chang Gung Health and Culture Village aged over 60.

You may qualify if:

  • residents of the Chang Gung Health and Culture Village
  • mostly independent and do not require nursing assistance
  • capable of managing their daily living activities
  • aged ≧ 60

You may not qualify if:

  • None.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chang Gung University

Taoyuan District, 333, Taiwan

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

blood and urine

MeSH Terms

Conditions

Sarcopenia

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Muscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and Symptoms

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Chih-Ming Lin, M.D.

    Chang Gung Memorial Hospital

    STUDY CHAIR

  • Mei-Ling Cheng, PhD

    Chang Gung University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Chih-Ming Lin, M.D.

CONTACT

886-975362603lin789@adm.cgmh.org.tw

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 17, 2017

First Posted

April 20, 2017

Study Start

March 6, 2017

Primary Completion

March 15, 2017

Study Completion

December 31, 2017

Last Updated

May 19, 2017

Record last verified: 2017-03

Locations

TW(1)